Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — ASX Small and Mid-Cap Conference 2020
15 slides from Zelira Therapeutics's conference presentation, Sep 10, 2020
Slide 1: Zelira Therapeutics: Developing and Marketing Clinically Validated Cannabis Medicines
For personal use only ZELIRA THERAPEUTICS A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND MARKETING CLINICALLY VALIDATED CANNABIS MEDICINES ASX: ZLD ASX Small and Mid-Cap Conference 2020 OTCQ B : Z L DA F W W W. Z E L I R AT X .CO M
Slide 2: Disclaimer & Important Notice
DISCLAIMER & IMPORTANT NOTICE Disclaimer For personal use only This presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Com
Slide 3: Investor Highlights
INVESTOR HIGHLIGHTS For personal use only Global access to the world’s largest and fastest growing cannabis markets Early mover advantage addressing need for clinically validated cannabis medicines Leading portfolio of validated products launching in 2020 Marketing strategy focused on differentiated
Slide 4: "Launch, Learn & Develop" for Rapid Commercialisation
“LAUNCH, LEARN & DEVELOP” FOR RAPID COMMERCIALISATION For personal use only LAUNCH LEARN DEVELOP • Generate proprietary formulations • Collect real-world patient data • Patient data informs and de-risks design of clinical trial • Launch products in global markets • Refine product to meet patient nee
Slide 5: Zelira's Global Commercialisation Strategy
ZELIRA’S GLOBAL COMMERCIALISATION STRATEGY For personal use only VA L U E A D D I N G • Clinically validated/Real World Data • Proprietary formulations • GMP-grade Branding Attracts Revenues from Global • IP protection • Branded Price Premium Distribution/Licensing Licensing (IP) Licensing strategy
Slide 6: Global Market Opportunities
GLOBAL MARKET OPPORTUNITIES For personal use only AUSTRALIA GERMANY USA 25M 83M 330M 2019 population 2019 population 2019 population 11K 65K 4M Registered medical Registered medical Registered medical cannabis patients2 cannabis patients4 cannabis patients1 30-50K 90% Pennsylvania Louisiana Forecast
Slide 7: Multiple Product Launches Planned for 2020
For personal use only MULTIPLE PRODUC T LAUNCHES PLANNED FOR 2020 8
Slide 8: HOPE for Autism
For personal use only HOPE FOR ™ AUTISM H OAutism P E ™ FTherapeutic O R A U T IMarket SM • HOPE™ developed with and for the Autistic community • Survey suggests HOPE™ improves autism-related behaviors Revenues: Licensed in Pennsylvania & Louisiana (Deal Structure: Upfronts + double digit royalty) H
Slide 9: Zenivol: World's First Clinically Validated Cannabis Drug for Chronic Insomnia
ZENIVOL™: WORLD’S FIRST CLINICALLY VALIDATED CANNABIS DRUG FOR CHRONIC INSOMNIA For personal use only Z E N I V O L ™ : PAT H TO M A R K E T • Phase 1B/2A clinical trial confirmed Zenivol™ safe, efficacious and improved quality of life • 36% Reduction in Insomnia Symptoms Manufacturing agreement for
Slide 10: Rich Product Pipeline Launching in 2020
RICH PRODUC T PIPELINE LAUNCHING IN 2020 On-track to launch 5 products in 2020 For personal use only Launch Market 2020 2021 HOPE™ 1 & 2 for Autism Launched ZENIVOL™ for Insomnia (2020) Revenues Oral Healthcare (2020) Aged Care (Parkinson’s) (2020) 11
Slide 11: Zelira's Five Sources of Revenues
Zelira’s Five Sources Of Revenues For personal use only LAUNCH & CLINICAL ORAL DERMATOLOGY PHARMA LEARN TRIALS HEALTH Autism Insomnia Toothpaste RX Pain Aged disorders Opioid Sparing Mouth Wash Full Spec CBD GI Autism Consumer Brand OTC 12
Slide 12: Corporate Snapshot
CORPORATE SNAPSHOT FINANCIALS (as at 7 Sep 2020) For personal use only AUD$ Share Price $0.057 SHARE PRICE (as at 7 Sep 2020) 52w Range $0.022 - 0.087 Current shares on issue* 1.14b* Market Capitalisation 63m Cash (Aug 2020)* $10.3m (before costs) Cash Burn (2020FY) $5.7m * Post $10.7m capital raise
Slide 13: Global Board of Directors
GLOBAL BOARD OF DIREC TORS UNITED STATES AUSTRALIA For personal use only Harry Karelis: Vice Chairman Osagie Imasogie: Chairman • Founding Director/Shareholder of numerous ASX-listed companies • Over 30 years in the field of law, finance, business management, including in the global medicinal cannab
Slide 14: Upcoming Milestones
Upcoming Milestones For personal use only Phase 2 Insomnia Trial - Successfully achieved primary and secondary endpoints Phase 1 Dose Escalation Chronic Pain Trial - Achieved primary and secondary endpoints Manufacturing agreement for Insomnia HOPE™ Products Licensing deal for third party to fund ne
Slide 15: Exposure to a Rapidly Emerging Global Industry
For personal use only ZELIRA THERAPEUTICS OFFERS INVESTORS EXPOSURE TO A RAPIDLY EMERGING GLOBAL INDUSTRY AT VERY ATTRACTIVE VALUATIONS AND SIGNIFICANT VALUE DRIVERS OVER THE NEXT 3-18 MONTHS 16
Zelira Therapeutics — ASX Small and Mid-Cap Conference 2020 on 6ix